#United States #Salt Lake City #Co-Diagnostics #Tuberculosis #CoSara

Co-Diagnostics Participates in Key Global Tuberculosis Events

Co-Diagnostics, Inc., a leading molecular diagnostics company based in Salt Lake City, is set to participate in three significant global tuberculosis (TB) events this November 2026. This initiative comes as the company prepares for the anticipated launch of its CoSara brand in India, addressing the country's urgent need for advanced TB testing solutions.

TB Events Overview

The first event is the 40th Stop TB Partnership Board Meeting, taking place from November 3-6, 2026, in Bali, Indonesia. This event, co-hosted by the Indonesian government and the Tahir Foundation, aims to unite global health leaders to discuss strategies for combating TB through improved diagnosis, treatment, and prevention methods.

Following this, on November 16, Co-Diagnostics will attend the 4th Annual New Tools Summit in Rio de Janeiro, Brazil. Here, the company will engage in discussions centered around the latest advancements in TB treatment and diagnostics. The summit promises to deliver insightful sessions, highlighting innovative tools that can revolutionize TB testing globally.

Finally, from November 17-20, Co-Diagnostics will be part of the Union World Conference on Lung Health, also in Rio de Janeiro. This significant gathering focuses on lung health, where practitioners, researchers, and advocates converge to share knowledge and best practices. Co-Dx's presence at these events underscores its commitment to enhancing lung health outcomes worldwide, particularly for those affected by TB.

CoSara's Launch in India

Co-Diagnostics is particularly excited about these events as they coincide with the forthcoming commercial launch of CoSara Diagnostics Pvt. Ltd.’s PCR Mycobacterium tuberculosis (MTB) test in India. With India bearing the highest burden of TB globally, the need for rapid and accurate diagnostics has never been more pressing. CoSara's technology aims to fulfill this need, providing decentralized TB testing that is crucial in combating the disease effectively.

The CoSara PCR technology not only enhances accessibility to TB testing but also aligns with global health initiatives aimed at reducing the burden of TB. This is especially vital in regions where TB remains a significant health challenge.

Co-Diagnostics' Mission

Co-Diagnostics, established in Utah, develops cutting-edge diagnostic technologies that analyze nucleic acid molecules (DNA and RNA). The company’s proprietary technology allows for the creation of specific tests designed for various health conditions, streamlining the diagnostic process. Their focus on the development of advanced PCR testing kits aims to revolutionize the diagnostics landscape in infectious diseases.

Co-Diagnostics also acknowledges the regulatory challenges in bringing such innovations to the market. The CoSara PCR Pro® instrument and associated tests are currently under review and are not approved for sale in the United States. However, the company remains optimistic about acquiring necessary approvals and expanding their testing capabilities, particularly in South Asia.

Conclusion

The future appears promising as Co-Diagnostics prepares for its participation in these pivotal TB events while simultaneously advancing its plans for the CoSara launch in India. This strategic involvement not only highlights the company's proactive approach in addressing global health challenges but also reinforces its commitment to improving diagnostic accessibility for TB and other infectious diseases. As the fight against TB continues to evolve, Co-Diagnostics stands at the forefront, ready to contribute its innovative diagnostics to save lives and improve health outcomes worldwide.